Prostate cancer patients are at increased risk of precancerous colon polyps

October 19, 2010

BUFFALO, NY -- Men with prostate cancer should be especially diligent about having routine screening colonoscopies, results of a new study by gastroenterologists at the University at Buffalo indicate.

Their findings show that persons diagnosed with prostate cancer had significantly more abnormal colon polyps, known as adenomas, and advanced adenomas than men without prostate cancer.

Results of the research were presented Oct. 19 at a 10:30 a.m. session at the American College of Gastroenterology meeting being held Oct. 15-20 in San Antonio, Texas.

While most adenomas are benign and don't become cancerous, there is evidence that most colon cancers begin as adenomas. Advanced adenomas carry an even higher colorectal cancer risk.

"Colon cancer and prostate cancer are two of the most common cancers in males," says Ognian Pomakov, MD, an author on the study. "However there are no published clinical studies to date that determined the prevalence of colorectal neoplasms in people with prostate cancer.

"Our study is the first to show that men with prostate cancer are at increased risk of developing colon cancer, and that it is especially important for these men not skip their routine colonoscopies."

Pomakov is an assistant professor in the Department of Medicine in the UB School of Medicine and Biomedical Sciences and an attending gastroenterologist at the Buffalo VA Medical Center. First author is Madhusudhan Sunkavalli, a UB internal medical resident.

The study involved 2,011 men who had colonoscopies at the Buffalo VAMC. The researchers reviewed patient records, colonoscopy reports and pathology reports, as well as data on the prevalence of adenomas, advanced adenomas, cancerous adenomas and their location within the colon.

The study compared the colonoscopy findings of 188 patients diagnosed with prostate cancer with the rest of the patients, who served as controls. Results showed that prostate cancer patients had significantly higher prevalence of abnormal polyps and advanced adenomas, compared to controls.

Forty-eight percent of prostate cancer patients had adenomas, compared to 30.8 percent of controls, and 15.4 percent had advanced adenomas compared to 10 percent of the men without prostate cancer.

"Our study findings suggest that patients with prostate cancer should definitely get their screening colonoscopy on time," says Pomakov. "In light of the limited resources of health-care systems, a priority should be given to such patients for colonoscopy screening.

"Further larger, and preferably prospective, studies should determine if screening for colorectal cancer should begin earlier than the currently recommended age of 50 for patients with prostate cancer."
-end-
Additional contributors to the research are Michael D. Sitrin, MD, UB gastroenterology chief; Roy D. Yen, MD, former GI fellow at UB, now on the faculty at University of Colorado, Denver; and Nirmit Kothari, MD, from St. Luke's Roosevelt Hospital Center in New York City.

The University at Buffalo is a premier research-intensive public university, a flagship institution in the State University of New York system and its largest and most comprehensive campus. UB's more than 28,000 students pursue their academic interests through more than 300 undergraduate, graduate and professional degree programs. Founded in 1846, the University at Buffalo is a member of the Association of American Universities.

University at Buffalo

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.